VIVUS — Technical Presentation (May 2010)
17 slides from VIVUS's technical presentation, May 17, 2010
Slide 1: Weight Loss With Controlled-Release Phentermine-Topiramate Drives Improvements in Obesity-Related Comorbidities
W. Timothy Garvey, MD1; Kishore Gadde, MD2; Craig Peterson, MS3; Wesley Day, PhD3 1Chair, Department of Nutrition Services, Professor of Nutrition Services, University of Alabama at Birmingham, Birmingham, AL; 2Duke University, Durham, NC; 3VIVUS, Inc., Mountain View, CA Weight Loss With Controlled-
Slide 2: Phentermine and Topiramate
Phentermine and Topiramate Phentermine (PHEN)1-3 FDA-approved (1959) as a short-term adjunct to diet and exercise Stimulates hypothalmic neurons to release norepinephrine that may cause: Appetite suppression by increasing blood leptin levels4 A decrease in neuropeptide Y production, which may result
Slide 3: Once-Daily, Low-Dose, Controlled Release Phentermine-Topiramate (PHEN/TPM CR)
PHEN/TPM CR or Qnexa® is an investigational weight loss therapy that is a combination of PHEN and TPM The 2 agents produce weight loss through different complementary mechanisms specific to each component Response with the combination is greater than the maximal response that could be obtained with
Slide 4: Integrated Analysis of PHEN-TPM CR: EQUIP and CONQUER study designs
Integrated Analysis of PHEN-TPM CR OB-302 (EQUIP) Compared full-dose (15/92 mg) and low-dose (3.75/23 mg) PHEN/TPM CR with placebo over 56 weeks of treatment in obese adults (<70 years of age with a BMI >35 kg/m2) Pooled analysis of two Phase 3, randomized, double-blind, placebo-controlled, multicen
Slide 5: Baseline Demographics
Baseline Demographics PHEN/TPM CR Placebo 3.75/23 7.5/46 15/92 (n = 1477) (n = 234) (n = 488) (n = 1479) Age (years), Mean (SD) 48.5 (11.4) 43.0 (11.1) 51.1 (10.4) 48.0 (12.0) Female, n (%) 1102 (74.6) 194 (82.9) 341 (69.9) 1094 (74.0) Race, n (%) Caucasian 1251 (84.7) 189 (80.8) 424 (86.9) 1235 (83
Slide 6: Primary Outcome: Percent Weight Loss at Week 56
Primary Outcome: Percent Weight Loss at Week 56 Percent Weight Loss From Baseline to Week 56 for CONQUER and EQUIP LS mean percent weight loss for the one-year ITT-LOCF population was maintained across all doses of PHEN/TPM CR at 56 weeks
Slide 7: Categorical Weight Loss at Week 56 (ITT-LOCF)
Categorical Weight Loss at Week 56 (ITT-LOCF) Percent of Subjects Reaching at Least 5%, 10%, and 15% Weight Loss at Week 56 for CONQUER and EQUIP
Slide 8: Change in Waist Circumference (WC)
Change in Waist Circumference (WC) From Baseline to Week 56 (ITT-LOCF)
Slide 9: Change in Blood Pressure
Change in Blood Pressure From Baseline to Week 56 (ITT-LOCF)
Slide 10: Change in Lipid Levels
Change in Lipid Levels From Baseline to Week 56 (ITT-LOCF)
Slide 11: Change in Triglycerides (TG)
Change in Triglycerides (TG) From Baseline to Week 56 (ITT-LOCF)
Slide 12: Change in Fasting Serum Glucose (FSG) Compared With Placebo
Change in Fasting Serum Glucose (FSG) Compared With Placebo (ITT-LOCF)
Slide 13: CONQUER: Change in Fasting Insulin (FI)
CONQUER: Change in Fasting Insulin (FI) From Baseline to Week 56 (ITT-LOCF)
Slide 14: CONQUER: Change in Inflammatory Biomarkers
CONQUER: Change in Inflammatory Biomarkers From Baseline to Week 56 (ITT-LOCF)
Slide 15: Treatment-Emergent Adverse Events Reported in >5% of Subjects
Treatment-Emergent Adverse Events Reported in >5% of Subjects in EQUIP and CONQUER EQUIP (N=1264) CONQUER (N=2485) % of Patients (N=3749) Placebo 3.75/23 15/92 Placebo 7.5/46 15/92 Dry mouth 3.7 6.7 17.0 2.4 13.5 20.8 Tingling 1.9 4.2 18.8 2.0 13.7 20.5 Constipation 6.8 7.9 14.1 5.9 15.1 17.4 Upper
Slide 16: Treatment-Emergent Adverse Events
Treatment-Emergent Adverse Events Most adverse events (AEs) were mild or moderate in severity Discontinuations due to AEs in the 1-year cohort: 9% (placebo) 12% (3.75/23) 12% (7.5/46) 18% (15/92) Reasons for discontinuations (occurring at >1% frequency): blurred vision, headache, insomnia, depressio
Slide 17: Summary
Summary This integrated analyses of two pivotal Phase 3 trials (EQUIP and CONQUER) demonstrates the efficacy and safety of PHEN/TPM CR across a broad subject population PHEN/TPM CR treatment achieved marked weight loss in subjects with and without comorbidities, and clinically meaningful reductions